Independent
Tenure on this board
11.5 yrs
2 nominees · 3 ballot items.
Elect two Class II directors (Mark Saad and Susan Mahony); ratify Deloitte & Touche LLP as independent auditors for 2026; and approve, by non-binding advisory vote, the compensation of the company’s named executive officers.
Elect Mark Saad and Susan Mahony as Class II directors to serve until the 2029 annual meeting and until their successors are elected and qualified.
Ratify the Audit Committee’s appointment of Deloitte & Touche LLP as Axsome’s independent registered public accounting firm for the year ending December 31, 2026.
A non-binding, advisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.
Proposal Three asks shareholders to cast a non-binding advisory vote to approve the compensation paid to the company’s named executive officers as disclosed in the Compensation Discussion and Analysis and compensation tables. Management seeks this approval as part of good governance under Dodd-Frank and SEC rules and to obtain stockholder feedback on executive pay design; the board has adopted an annual say-on-pay vote and recommends a vote FOR. The company’s disclosed program emphasizes pay-for-performance with a mix of base salary, at-risk annual cash incentives (with target and maximum payout levels, and a 150% payout for 2025 based on achieved corporate goals), and long-term equity incentives comprising RSUs, stock options and performance stock units (PSUs) tied to multi-year revenue and clinical/regulatory milestones. The Compensation Committee engaged an independent consultant and used a peer group benchmarking process; it also described robust governance features such as clawback policies, prohibitions on hedging and double-trigger change-in-control provisions for equity. Recent context includes strong prior say-on-pay support (~98% in 2025), significant 2025 corporate achievements (commercial growth of Auvelity, commercial launch of Symbravo, clinical/ regulatory progress) that the committee cites in justifying 150% payouts, and a shift in 2026 equity mix to RSUs and PSUs to align with peer practices. The vote is advisory and non-binding: a FOR vote signals endorsement and can influence future compensation decisions, while a AGAINST or withheld vote would signal stockholder concern but would not automatically change pay arrangements. Analysts evaluating the proposal should weigh the company’s clear alignment mechanisms (performance-based PSUs, multi-year vesting, recoupment policies) against the substantial realized and potential pay outcomes for executives, especially given large equity-based gains realized by certain executives in recent years. The board’s recommendation reflects confidence in the design and in the Compensation Committee’s process, but investors should consider pay quantum, realized pay volatility driven by equity grants/exercises, and the non-binding nature of the vote when forming a governance assessment.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.00% | 2,058,170 | $348M |
| 2 | BlackRock, Inc. | 3.91% | 2,009,868 | $340M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3.77% | 1,937,752 | $328M |
| 4 | FMR LLC | 2.50% | 1,284,268 | $217M |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.46% | 1,266,092 | $214M |
| 6 | BlackRock, Inc. | 2.44% | 1,257,486 | $213M |
| 7 | Invesco Ltd. | 2.30% | 1,184,888 | $200M |
| 8 | Deep Track Capital, LP | 2.14% | 1,100,000 | $186M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.97% | 1,015,163 | $172M |
| 10 | STATE STREET CORP | 1.92% | 986,809 | $167M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.